Resolvin D1,resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes

Abstract

Pro-resolving, docosahexaenoic acid-derived mediators have recently emerged as important potential therapeutic agents for the amelioration of complications arising from inflammation, such as vascular disease, asthma, acute lung injury and colitis. While resolvin D1 (RVD1), resolvin D2 (RVD2) and maresin 1 (MaR1) are established pro-resolvins, their mechanisms of action remain unclear. Here we show that, in LPS-stimulated primary human monocytes, RVD1, RVD2 and MaR1 each suppress the release of pro-inflammatory cytokines (TNF, IL-1β, IL-8) and the innate/adaptive bridging cytokine, IL-12 p40, while simultaneously augmenting the production of the anti-inflammatory cytokine, IL-10. Such resolving activity is accompanied by the increased phosphorylation (enhanced anti-inflammatory state) of glycogen synthase kinase 3β (GSK3β) along with increased phosphorylation (activation) of Akt, SGK1 and CREB but not MAPK-related molecules. Gain and loss of function experiments confirm a key role for GSK3β and CREB in the anti-inflammatory actions of resolvins. These results suggest that induction of the GSK3β anti-inflammatory axis is a common mechanism of action for RVD1, RVD2 and MaR1.

Keywords

CREB GSK3β inflammation LPS maresin resolvin

Introduction

There are multiple potentially convergent endogenous pathways that serve to limit inflammation and promote its resolution, thereby protecting the host from collateral damage. Such innate braking systems include the α7 acetylcholine receptor-dependent cholinergic; glycogen synthase kinase 3β (GSK3β); serum and glucocorticoid-regulated kinase 1 (SGK1); and Wnt anti-inflammatory signaling axes.^1–5 The identification of omega-3 polyunsaturated fatty acid-derived resolving mediators, including the docosahexaenoate metabolites resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid; RVD1), resolvin D2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid; RVD2) and maresin-1 (7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid; MaR1), have added to the emergent understanding that the resolution of inflammation is highly dynamic.^6–9

In vivo, RVD1, RVD2 and/or MaR1 have been shown to suppress pro-inflammatory cytokine production during multiple inflammatory conditions with protective consequences, including experimental uveitis,¹⁰ hepatic ischemia/reperfusion injury,¹¹ peritonitis,¹² periodontitis,¹³ acute lung injury,^14–18 colitis,^19,20 endometriosis²¹ and endotoxic shock.²² Resolvins have also been reported to abet caspase-dependent neutrophil apoptosis,^14,23 to augment efferocytosis^24,25 and to promote the de novo generation of regulatory T cells.²⁶ All such processes are associated with the resolution of inflammation.

In vitro, RVD1, RVD2 and/or MaR1 suppress pro-inflammatory cytokine release in several innate immune cell types that have been exposed to variant inflammatory mediators, such as bronchial epithelial cells,^27,28 corneal epithelial cells,²⁹ macrophages³⁰ and gingival fibroblasts.³¹ Furthermore, resolving mediators, particularly RVD1 and MaR1, have been shown to suppress NF-κB activation in cells such as microglia,^32,33 smooth muscle cells³⁴ and vascular endothelial cells,³⁵ as well as in several inflammatory disease animal models, including acute lung injury,^15,18,36 colitis¹⁹ and sepsis.³⁷ However, the events leading to inhibition of NF-κB signaling have yet to be fully elucidated.

GSK3β is constitutively active and promotes inflammation in the context of TLR engagement. However, phosphorylation of GSK3β at Ser9 results in inhibition of the production of pro-inflammatory cytokines.^1,2,38 Zhang et al.¹¹ recently suggested that RVD1 suppression of pro-inflammatory cytokines and attenuation of hepatic ischemia/reperfusion injury is mediated, at least in part, by a mechanism involving enhanced phosphorylation of Akt. Several other groups have also reported that PI3K-Akt-related signaling events are key to the protective efficacy of RVD1 protection against inflammatory damage.^16,39,40 Further, resolvin E1 (5S,12R,18R)-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; RVE1) and lipoxin A4 (5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid; LXA4) have both been reported to influence the activation state of Akt.^41,42 PI3K is an activator of Akt, while Akt is an established kinase inactivator of the central mediator of inflammation, GSK3β.^1,2,38 Therefore, we hypothesized that the pro-resolving activities of RVD1, RVD2 and MaR1 may involve the inactivation of GSK3β and thus augmentation of GSK3β anti-inflammatory axis. We set out to test this hypothesis in LPS-stimulated primary human monocytes.

Materials and methods

Materials

Monocyte isolation kits were from Miltenyi Biotec (Auburn, CA, USA). RPMI Complete (RPMI 1640 medium supplemented with FBS, 2-mercaptoethanol, sodium pyruvate, L-glutamine and HEPES) was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Ultrapure LPS from Escherichia coli 0111:B4 was purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-phospho-NF-κB p65 (Ser536), pGSK3β (Ser9), pCREB (Ser133), pERK1/2 (Thr202/Tyr204), pSAPK/JNK (Thr183/Tyr185), p-p38 MAPK (Thr180/Tyr182), GAPDH, β-actin and goat anti-rabbit IgG-HRP Abs, as well as non-targeted SignalSilence Control siRNA were from Cell Signaling Technology (Danvers, MA, USA). Anti-pSGK (Ser422) goat Abs came from Santa Cruz Biotechnology (Santa Cruz, CA, USA), while mouse anti-goat IgG-HRP Abs were from Rockland Immunochemicals (Limerick, PA, USA). MaR1, RVD1 and RVD2 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Enhanced chemiluminescence kits were purchased from Thermo Scientific (Rockford, IL, USA). Cytokine ELISA kits (TNF, IL-10, IL-8 and IL-1β) were from eBioscience (San Diego, CA, USA). IL-12/23 p40 ELISA kits came from Boster Immunoleader (Pleasanton, CA, USA). The plasmids HA pcDNA3 and HA pcDNA3-GSK3β(S9A), were gifts from Jim Woodgett (Addgene; plasmids 10792, 14754). CREB siRNA was purchased from Dharmacon (Lafayette, CO, USA).

Preparation of human monocytes

Primary human monocytes were purified from anonymized, citrated whole blood by indirect magnetic monocyte isolation, as approved by the University of Louisville, Institutional Review Board (12.0346). This procedure routinely results in >95% pure CD14⁺ cells, as shown by flow cytometry. Human monocytes were cultured at 37℃ and 5% CO₂ atmosphere, in complete RPMI plus or minus stimulating agents, as described below. Monocyte viability was evaluated by trypan blue exclusion.

Cytokine release by human monocytes

Primary human monocytes (200,000 cells/well) were stimulated or not with LPS and/or MaR1, RVD1 or RVD2, as described in the figure legends. Ethanol solvent controls, equivalent to the highest solvent concentration in the resolving stimulations, were included. MaR1, RVD1 or RVD2 was added 30 min prior to TLR4 stimulation with LPS. Cell-free supernatants were harvested at 20 h and assayed for cytokine levels by ELISA, according to the manufacturer’s instructions.

Expression of GSK3β pathway molecules

Levels of Ser⁵³⁶ phosphorylated NF-κB p65, Ser⁹ phosphorylated GSK3β, as well as Ser¹³³ phosphorylated CREB, Ser⁴²² phosphorylated SGK-1, pSYK, pERK1/2, pSAPK/JNK, p38 MAPK, β-actin and GAPDH were determined by Western blot using whole-cell lysates (10 µg protein). Images were visualized by enhanced chemiluminescence and acquired using the ImageQuant LAS 4000 system (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Expression levels are presented as mean intensity ratios relative to a housekeeping gene, as determined by densitometry using Image J software (National Institutes of Health, Bethesda, MD, USA).

Pharmacological inhibition of GSK3β pathway

The contribution of GSK3β to the inhibition of TLR4-induced cytokine induction in human monocytes was further explored through the use of the pharmaceutical inhibitor, SB216763. Monocytes were pre-treated with SB216763 for 2 h prior to LPS (1 µg/ml) stimulation with or without an additional pre-LPS stimulation with MaR1. DMSO (0.05%) and ethanol (as described above) solvent controls were included. Cell-free supernatants were assayed for cytokine levels by ELISA 20 h after the addition of LPS.

Transfection of GSK3β(S9A) and siRNA

Transfection of monocytes with non-targeting control siRNA and siRNA-CREB, as well as plasmids pcDNA3-GSK3β(S9A) and pcDNA3 (empty vector control) was achieved by electroporation using Lonza Nucleofector technology (Allendale, NJ, USA), following the manufacturer’s protocol. Transfected monocytes were stimulated with LPS on d 3 post transfection. Cell-free supernatants were assayed for IL-8 or IL-10 by ELISA 20 h after the addition of LPS.

Statistical analyses

Statistical significance between groups was evaluated by the analysis of variance and the Tukey multiple comparison test using the InStat program (GraphPad, San Diego, CA, USA). Differences between groups were considered significant at the level of P ≤ 0.05. Some Western blot-related data refer to representative blots. All other data are presented as the arithmetic mean ± SD of three biological replicates.

Results

Resolvin D1, resolvin D2 and maresin-1 suppress LPS-induced pro-inflammatory cytokines in primary human monocytes

Initial experiments established that resolvins were highly efficient inhibitors of the release of IL-8, selected as a typical LPS-induced cytokine, from TLR4-engaged human monocytes across a broad range of concentrations (Figure 1).

Figure 1.

Inhibition of LPS-induced IL-8 by variant resolvin doses. Twenty h cell-free supernatants were collected from primary human monocytes stimulated with or without LPS (1 µg/ml) in the presence or absence of (a) MaR1 (0–5 μM), (b) RVD1 (0–60 nM) or (c) RVD2 (0–2 μM). The production of IL-8 was determined by ELISA. Data represent the arithmetic mean ± SD of three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001.

Subsequently, the ability of RVD1, RVD2 and MaR1 to inhibit inflammation-inducing cytokines (IL-1β, TNF; all P < 0.05) and the p40 sub-unit of the innate-adaptive bridging cytokine, IL-12 (all P < 0.05), was determined (Figure 2). The IC₅₀ values for suppression of TNF, IL1β, IL-8 and IL-12 p40 are presented in Table 1. Resolvins alone did not influence pro-inflammatory cytokine secretion in innate cells (Figures 1 and 2). Furthermore, resolvins had no significant influence on monocyte viability at the concentrations employed, as determined by trypan blue exclusion.

Figure 2.

MaR1, RVD1 and RVD2 each inhibit LPS-induced pro-inflammatory cytokines [(a) IL-1β, (b) TNF and (c) IL-12 p40]. Twenty h cell-free supernatants were collected from primary human monocytes stimulated with or without LPS (1 µg/ml) in the presence or absence of MaR1 (1 μM), RVD1 (30 nM) or RVD2 (1 μM). The production of pro-inflammatory cytokines was determined by ELISA. Data represent the arithmetic mean ± SD of three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001.

Table 1.

Resolving mediator concentration required to inhibit 50% cytokine release (IC₅₀) from TLR4-engaged primary innate cells.

Cytokine	MaR1 (μM)	RVD1 (nM)	RVD2 (μM)
TNF	1.0	78.9	3.6
IL-1β	2.8	44.0	2.4
IL-8	1.2	172.1	1.4
IL-12 p40	3.0	84.9	3.4

LPS- (1 µg/ml) induced cytokine release from 200,000 monocytes was measured in 20 h cell-free supernatants by ELISA.

Resolvin D1, resolvin D2 and maresin-1 augment LPS-induced anti-inflammatory IL-10 release

Concomitant with the suppression of pro-inflammatory cytokines, RVD1, RVD2 and MaR1 each augmented the release of the anti-inflammatory cytokine, IL-10 (all P < 0.05) from TLR4-engaged innate cells, as shown in Figure 3. Resolvins alone did not influence IL-10 production in human monocytes (Figure 3).

Figure 3.

MaR1, RVD1 and RVD2 each augment LPS-induced IL-10 release. Twenty h cell-free supernatants were collected from primary human monocytes stimulated with or without LPS (1 µg/ml) in the presence or absence of MaR1 (1 μM), RVD1 (30 nM) or RVD2 (1 μM). The production of IL-10 was determined by ELISA. Data represent the arithmetic mean ± SD of three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001.

Resolvin D1, resolvin D2 and maresin-1 phospho-inactivate GSK3β while activating CREB in LPS-stimulated innate cells

As can be seen in Figure 4, RVD1, RVD2 and MaR1 each induced the efficient phosphorylation of the central mediator of inflammation, GSK3β, at Ser9—a potent inflammation inhibiting event. The activation status of SGK1, an anti-inflammatory kinase,³ was similarly enhanced. Phosphorylation of SYK, a TLR ligand and inflammatory enhancer,⁴³ pERK1/2, pSAPK/JNK and/or p38 MAPK were unaffected (data not shown). However, RVD1, RVD2 and MaR1 all augmented the phosphorylation of CREB at Ser133 in TLR4-engaged innate cells, while the NF-κB (p65) signal was diminished. Importantly, resolvins alone did not influence the activation state of any of the inflammatory signaling molecules examined.

Figure 4.

MaR1, RVD1 and RVD2 promote the phosphorylation of GSK3β and CREB but reduce p65 phosphorylation. (a) Western blots of whole-cell lysates (10 µg protein) from LPS-stimulated and unstimulated primary human monocytes. Blots were probed with Abs to phospho-p65 (S536), pSGK1 (S422), pAkt (S473), pGSK3β (S9) and pCREB (S133), as well as total GAPDH as a loading control. Densitometric quantification was performed by determination of the ratios of (b) pSGK, (c) pGSK3β, (d) pAKT, (e) pCREB and (f) pNFκB to total GAPDH signal using Image J software. MaR1 (1 μM), RVD1 (30 nM) or RVD2 (1 μM) concentrations were used. Representative blots are presented. *P < 0.05, **P < 0.01, ***P < 0.001 compared with LPS 60 min. ^#P < 0.05, ^##P < 0.01, ^###P < 0.0001 compared with LPS 15 min.

GSK3β(S9A) and GSK3β blockade alter the anti-inflammatory properties of MaR1

As all data suggested that resolvins function similarly (Figures 1 –4), the mechanisms of resolvin-induced innate suppression were further elucidated using MaR1. The GSK3β inhibitor, SB216763, enhanced resolvin suppression of pro-inflammatory cytokine (IL-8; P < 0.05) production in the context of LPS concomitant with increased anti-inflammatory cytokine (IL-10; P < 0.001) secretion (Figure 5A, B). The augmentation by SB216763 suggests that inhibition of GSK3β by MaR1 is effective but incomplete. More importantly, however, MaR1 was unable to inhibit LPS-induced IL-8 production in monocytes transfected with pcDNA3-GSK3β(S9A) which expresses a GSK3β isoform that cannot be phosphorylatively inactivated (Figure 5C).

Figure 5.

Inhibition of GSK3β or expression of GSK3βS9A alter the inflammatory response to LPS in MaR1-treated monocytes. (a) IL-10 and (b) IL-8 concentrations in 20 h cell-free supernatants were collected from primary human monocytes stimulated or not with LPS (1 µg/ml) in the presence or absence of MaR1 (1 μM) with and without GSK3β blockade by SB216763. (c) IL-8 release into 20-h cell-free supernatants of primary monocytes containing a plasmid expressing constitutively active GSK3βS9A (or empty vector) and stimulated with or without LPS (1 µg/ml) in the presence or absence of MaR1 (1 μM). Data represent the arithmetic mean ± SD of three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001.

CREB silencing promotes a pro-inflammatory axis

As presented in Figure 6, siRNA-mediated creb silencing confirmed the functional role of CREB in resolvin-mediated augmentation of anti-inflammatory IL-10 production in TLR4-engaged monocytes. CREB levels were successfully knocked down by transfecting innate cells with creb-specific siRNA (Figure 6A, B). Such creb silencing led to the enhancement of pro-inflammatory cytokine (IL-8; P < 0.05) release concomitant with suppression of anti-inflammatory cytokine (IL-10, P < 0.001) secretion in MaR1- and LPS-exposed monocytes (Figure 6C, D).

Figure 6.

CREB silencing abrogates MaR1-mediated IL-10 enhancement and Il-8 suppression in response to LPS. Successful knockdown of CREB by siRNA was confirmed by (a) Western blot and (b) densitometry. (c) IL-10 and (d) IL-8 concentrations in 20 h cell-free supernatants were collected from primary human monocytes stimulated with or without LPS (1 µg/ml) in the presence or absence of MaR1 (1 μM) with and without creb silencing. (a) and (b) are representative data. (c) and (d) are presented as the arithmetic mean ± SD of three biological replicates. *P < 0.05, ***P < 0.001.

Discussion

Several key studies have established a critical role for endogenous and exogenous docosahexaenoic acid-derived lipid mediators, which appear to be share a degree of receptor commonality,^44–46 in the resolution of inflammation.^7,8,47,48 Interestingly, Hsiao et al. have suggested that RVD1 may increase the concentration of the anti-inflammatory cytokine, IL-10, in the lungs of smoke-exposed mice.⁴⁹ We show that RVD1, RVD2 and MaR1 are each efficacious inhibitors of multiple pro-inflammatory cytokines (IL-1β, IL-8, TNF) produced by monocytes in response to stimulation with the classic TLR-4 agonist, LPS. We also show, for the first time, that all three resolvins suppress the innate/adaptive bridging, T-cell-stimulating and angiogenic cytokine, IL-12 p40, while concomitantly increasing the expression of IL-10, the classic anti-inflammatory cytokine.

In order to harness and refine the anti-inflammatory therapeutic potential of resolvins, it is first necessary to understand their mechanisms of action. To this end, Nordgren et al.²⁸ have reported that while MaR1 pretreatment did not alter the activation of NF-κB, AP-1 or SP-1 in pollution particle-stimulated bronchial epithelial cells it did alter serum response element signaling. However, pollution particles may activate the innate response in a different manner than microbe-associated molecular patterns, and most studies have found an inhibitory effect of resolvins on the key pro-inflammatory transcriptional activator, NF-κB.^32–35 Gilbert et al.³⁹ have reported that RVD1 promotes Akt activation and that the efficacy of RVD1 to suppress myocardial ischemia/reperfusion injury is abrogated by the PI3K inhibitor, LY-294002. Of the resolving mediators, RVE1 and LXA4 are among the better characterized, from a signaling perspective. Ohira et al.⁴¹ have also reported that RVE1 can induce Akt–mTOR pathway activation, even in the absence of a primary pro-inflammatory mediator, in Chinese hamster ovary cells expressing the RVD1 receptor, Chem 23.⁴¹ Prieto et al.⁴² have established that LXA4 can activate the PI3K/Akt axis in macrophages. Wang et al.¹⁶ have shown that the PI3K inhibitor (LY294002) blocks RVD1-induced expression of epithelial sodium channel α (ENaCα) in vitro and reduced the efficacy of RVD1 in suppressing pulmonary inflammation in a LPS-induced acute lung injury model. Other reports have also suggested RVD1 action may be mediated by PI3K.⁴⁰ PI3K is an activator of Akt, while Akt is an established phosphorylative inactivator of the central mediator of inflammation, GSK3β.^1,2,38 Furthermore, the ratios of NF-κB and CREB help direct the direction and intensity of the inflammatory response, with activity of the IL-10 gene being driven, in part, by interactions of CREB with the IL-10 cAMP-responsive element.³⁸

We have augmented the PI3k–Akt-related literature by establishing that RVD1, RVD2 and MaR1 each enhance the phosphorylation of GSK3β (inactivation) and CREB (activation), while reducing the amount of phosphorylated p65 relative to pCREB or GADPH. Interestingly, the activation state of SGK1, which we have recently established to be a potent anti-inflammatory mediator in the context of TLR-engagement,³ was also enhanced by MaR1, RVD1 and RVD2. However, the phosphorylation state of SYK, a TLR ligand and inflammatory enhancer,⁴³ and several MAPK-related molecules was not influenced by resolvins. All Abs employed were established and commonly employed commercial preparations. However, cross-reactivity with non-target proteins remains a possibility. To this end, it was important to verify key immunoblot-derived data by a combination of pharmaceutical inhibition, gene silencing and gain- or loss-of-function approaches. Plasmid-derived GSK3βS9A, which cannot be phosphorylatively inactivated, abrogated the anti-inflammatory capability of MaR1. To further confirm the importance of CREB in resolvin-enhanced IL-10 response, siRNA-mediated creb silencing resulted in inflammatory polarization in the opposite direction to the GSK3β inhibitor SB216763, i.e., creb gene silencing enhanced pro-inflammatory cytokine (IL-8) release while suppressing MaR1 augmentation of anti-inflammatory IL-10 production in TLR4-engaged monocytes.

We have examined innate suppression in the context of a professional cytokine-producing cell type (monocytes) engaged by a highly potent TLR agonist (E. coli LPS), an in vitro system that has required the utilization of relatively high doses of resolving, with IC₅₀ values generally in the μM range. By comparison, inhibitory concentrations of resolving agonists used to suppress capsaicin (100 nM)-induced transient receptor potential vanilloid 1 currents in neurons (IC₅₀ ≈ 0.5 nM)⁵⁰ or to reduce the TNF-induced IL-1β transcript signal in glioma cells (IC₅₀ ≈ 50 pM)⁵¹ are much lower. Others, however, have employed micromolar concentrations when determining the efficacy of pro-resolvins in the inhibition of cytokine production following direct engagement of TLRs in dedicated innate cells.^29,30 Nevertheless, it remains to be seen if the same phenomena demonstrated in vitro herein occur in vivo.

There are many potential mechanisms of action of pro-resolving mediators, as recently reviewed.^46,51–54 We have focused on the TLR4 (LPS)-GSK3β axis and established that resolvins appear to induce the GSK3β anti-inflammatory axis leading to enhancement of the active form of the IL-10 transcriptional enhancer, CREB. Further elucidation of common and divergent mechanisms of action of such resolvins should facilitate the translation of RVD1, RVD2 and MaR1 for the amelioration of infection-driven inflammation and, perhaps, other conditions associated with dysregulation of the innate immune response. Indeed, it may even be possible to manipulate resolvin-related signaling events in order to up- or down-regulate the direction and intensity of the innate response, depending on the clinical necessity.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by NIDCR grants DE017680 (DAS), DE023633 (HW), DE025409 (SMU) and DE017921, DE011111 (RJL).

References

Wang

Kumar

Lamont

Scott

. GSK3beta and the control of infectious bacterial diseases. Trends Microbiol 2014; 22: 208–217.

Rehani

Scott

Renaud

. Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim Biophys Acta 2008; 1783: 375–382.

Zhou

Gao

Duan

. Inhibition of serum- and glucocorticoid-inducible kinase 1 enhances TLR-mediated inflammation and promotes endotoxin-driven organ failure. FASEB J 2015; 29: 3737–3749.

Di Liddo

Bertalot

Schuster

. Anti-inflammatory activity of Wnt signaling in enteric nervous system: in vitro preliminary evidences in rat primary cultures. J Neuroinflammation 2015; 12: 23–23.

Wang

Liao

Ochani

. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216–1221.

Serhan

Gotlinger

Hong

. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 2006; 176: 1848–1859.

Serhan

Yang

Martinod

. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15–23.

Spite

Norling

Summers

. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461: 1287–1291.

Duffield

Hong

Vaidya

. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 2006; 177: 5902–5911.

10.

Rossi

Di Filippo

Gesualdo

. Protection from endotoxic uveitis by intravitreal Resolvin D1: involvement of lymphocytes, miRNAs, ubiquitin-proteasome, and M1/M2 macrophages. Mediators Inflamm 2015; 2015: 149381–149381.

11.

Zhang

Shu

Chang

. Resolvin D1 protects against hepatic ischemia/reperfusion injury in rats. Int Immunopharmacol 2015; 28: 322–327.

12.

Recchiuti

Codagnone

Pierdomenico

. Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. FASEB J 2014; 28: 3090–3102.

13.

Maekawa

Hosur

Abe

. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3beta-C/EBPbeta pathway. Nat Commun 2015; 6: 8272–8272.

14.

Gong J, Liu H, Wu J, et al. 2015. Maresin 1 Prevents Lipopolysaccharide- Induced Neutrophil Survival and Accelerates Resolution of Acute Lung Injury. Shock 2015; 44: 371--380.

15.

Wang

Yuan

Yao

. Effects of resolvin D1 on inflammatory responses and oxidative stress of lipopolysaccharide-induced acute lung injury in mice. Chin Med J (Engl) 2014; 127: 803–809.

16.

Wang

Zheng

Cheng

. Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na,K-ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury. J Immunol 2014; 192: 3765–3777.

17.

Yaxin

Shanglong

Huaqing

. Resolvin D1 attenuates lipopolysaccharide induced acute lung injury through CXCL-12/CXCR4 pathway. J Surg Res 2014; 188: 213–221.

18.

Eickmeier

Seki

Haworth

. Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 2013; 6: 256–266.

19.

Bento

Claudino

Dutra

. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 2011; 187: 1957–1969.

20.

Marcon

Bento

Dutra

. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J Immunol 2013; 191: 4288–4298.

21.

Dmitrieva

Suess

Shirley

. Resolvins RvD1 and 17(R)-RvD1 alleviate signs of inflammation in a rat model of endometriosis. Fertil Steril 2014; 102: 1191–1196.

22.

Murakami

Suzuki

Tamura

Nagaoka

. Suppressive action of resolvin D1 on the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice. Exp Ther Med 2011; 2: 57–61.

23.

Gong

. Maresin 1 mitigates LPS-induced acute lung injury in mice. Br J Pharmacol 2014; 171: 3539–3550.

24.

Chiang

Dalli

Colas

Serhan

. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med 2015; 212: 1203–1217.

25.

McCauley

Dalli

Koh

. Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. J Immunol 2014; 193: 26–29.

26.

Krishnamoorthy

Burkett

Dalli

. Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. J Immunol 2015; 194: 863–867.

27.

Nordgren

Bauer

Heires

. Maresin-1 reduces airway inflammation associated with acute and repetitive exposures to organic dust. Transl Res 2015; 166: 57–69.

28.

Nordgren

Heires

Wyatt

. Maresin-1 reduces the pro-inflammatory response of bronchial epithelial cells to organic dust. Respir Res 2013; 14: 51–51.

29.

Erdinest

Ovadia

Kormas

Solomon

. Anti-inflammatory effects of resolvin-D1 on human corneal epithelial cells: in vitro study. J Inflamm (Lond) 2014; 11: 6–6.

30.

Palmer

Mancuso

Weiss

. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol 2011; 90: 459–470.

31.

Khaled

Shibani

Labban

. Effects of resolvin D1 on cell survival and cytokine expression of human gingival fibroblasts. J Periodontol 2013; 84: 1838–1846.

32.

Tian

Zhang

. Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson's disease rat model. Biochem Biophys Res Commun 2015; 460: 799–805.

33.

Tan

Zhou

. Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci Ther 2013; 19: 235–243.

34.

Akagi

Chen

Toy

. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J 2015; 29: 2504–2513.

35.

Chatterjee

Sharma

Chen

. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLoS One 2014; 9: e113480–e113480.

36.

Liao

Dong

. Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARgamma/NF-kappaB pathway. Respir Res 2012; 13: 110–110.

37.

Chen

Fan

. Resolvin D1 improves survival in experimental sepsis through reducing bacterial load and preventing excessive activation of inflammatory response. Eur J Clin Microbiol Infect Dis 2014; 33: 457–464.

38.

Martin

Rehani

Jope

Michalek

. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777–784.

39.

Gilbert

Bernier

Bourque-Riel

. Resolvin D1 Reduces Infarct Size Through a Phosphoinositide 3-Kinase/Protein Kinase B Mechanism. J Cardiovasc Pharmacol 2015; 66: 72–79.

40.

Zheng

. Novel biphasic role of resolvin D1 on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts is partly through PI3K/AKT and ERK2 pathways. Mediators Inflamm 2013; 2013: 964012–964012.

41.

Ohira

Arita

Omori

. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 2010; 285: 3451–3461.

42.

Prieto

Cuenca

Traves

. Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways. Cell Death Differ 2010; 17: 1179–1188.

43.

Chaudhary

Fresquez

Naranjo

. Tyrosine kinase Syk associates with toll-like receptor 4 and regulates signaling in human monocytic cells. Immunol Cell Biol 2007; 85: 249–256.

44.

Strichartz

Serhan

. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 2011; 34: 599–609.

45.

Keinan

Leigh

Nelson

. Understanding resolvin signaling pathways to improve oral health. Int J Mol Sci 2013; 14: 5501–5518.

46.

Cash

Norling

Perretti

. Resolution of inflammation: targeting GPCRs that interact with lipids and peptides. Drug Discov Today 2014; 19: 1186–1192.

47.

Spite

Summers

Porter

. Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br J Pharmacol 2009; 158: 1062–1073.

48.

Sun

Uddin

. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 2007; 282: 9323–9334.

49.

Hsiao

Sapinoro

Thatcher

. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS One 2013; 8: e58258–e58258.

50.

Serhan

Dalli

Karamnov

. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 2012; 26: 1755–1765.

51.

Serhan

Hong

Gronert

. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025–1037.

52.

Serhan

Chiang

Dalli

. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol 2015; 27: 200–215.

53.

Serhan

Chiang

Dalli

Levy

. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol 2015; 7: a016311–a016311.

54.

Headland

Norling

. The resolution of inflammation: Principles and challenges. Semin Immunol 2015; 27: 149–160.